Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHI3L1 | P36222 | 2/20 | 0.38 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.38 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.38 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.38 |
| ▸ | SORD | Q00796 | 9/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19012567 | 1.00 | CHI3L1 (0.38) | CHI3L1CHIT1CHI3L2CHIASORD | |
| SCHEMBL18436131 | 0.83 | PDE10A (0.39) | CHI3L1CHIT1CHI3L2CHIASORD | |
| SCHEMBL19012761 | 0.83 | NPC1 (0.43) | CHI3L1CHIT1CHI3L2CHIASORD | |
| SCHEMBL17128393 | 0.82 | ACACB (0.39) | CHI3L1SORDALDH1A1NPC1RAB9A | |
| SCHEMBL21336728 | 0.82 | SORD (0.38) | CHI3L1SORDNPC1RAB9A | |
| SCHEMBL17128394 | 0.82 | SORD (0.38) | SORDHRH3NPC1RAB9A | |
| SCHEMBL18436836 | 0.82 | SORD (0.38) | CHI3L1SORDNPC1RAB9A | |
| SCHEMBL19001056 | 0.80 | TRPV1 (0.40) | SORDNPC1RAB9A | |
| SCHEMBL19001102 | 0.80 | TRPV1 (0.40) | SORDNPC1RAB9A | |
| SCHEMBL19012605 | 0.80 | ACACB (0.43) | SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | CHI3L1 2571/4885CHIT1 4864/4885CHI3L2 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.